Kevin Krause
Corporate Officer/Principal bei AN2 THERAPEUTICS, INC.
Vermögen: 72 764 $ am 30.04.2024
Profil
Kevin Krause is currently the Chief Strategy Officer at AN2 Therapeutics, Inc. He previously worked as the Senior Director-Corporate Development at Achaogen, Inc. from 2015 to 2019 and as a Member-Clinical Microbiology at Cerexa, Inc. from 2010 to 2014.
He received an undergraduate degree from San Francisco State University and an MBA from Haas School of Business.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
AN2 THERAPEUTICS, INC.
0,11% | 15.03.2024 | 31 914 ( 0,11% ) | 72 764 $ | 30.04.2024 |
Aktive Positionen von Kevin Krause
| Unternehmen | Position | Beginn |
|---|---|---|
| AN2 THERAPEUTICS, INC. | Corporate Officer/Principal | 01.08.2021 |
Ehemalige bekannte Positionen von Kevin Krause
| Unternehmen | Position | Ende |
|---|---|---|
| ACHAOGEN | Corporate Officer/Principal | 01.06.2019 |
Cerexa, Inc.
 Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Corporate Officer/Principal | 01.12.2014 |
Ausbildung von Kevin Krause
| Haas School of Business | Masters Business Admin |
| San Francisco State University | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 1 |
|---|---|
| AN2 THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 2 |
|---|---|
Achaogen, Inc.
 Achaogen, Inc. Pharmaceuticals: MajorHealth Technology Achaogen, Inc. engages in developing and commercializing innovative antibacterial agents for multi-drug resistant gram-negative infections. The firm is also involved in the development of C-Scape, an orally administered antibiotic to address a serious unmet need for an effective oral treatment for patients with complicated urinary tract infections, including pyelonephritis caused by extended spectrum beta-lactamases producing Enterobacteriaceae. The company was founded by Nathaniel Eames David, Floyd E. Romesberg, and Peter G. Schultz in June 2002 and is headquartered in South San Francisco, CA. | Health Technology |
Cerexa, Inc.
Cerexa, Inc. Pharmaceuticals: MajorHealth Technology Cerexa, Inc. develops biopharmaceutical products. It is focuses on developing, acquiring and commercializing antibiotics to treat life-threatening, hospital-based infections. Cerexa's compound PPI-0903 is a cephalosporin used in treatment for complicated skin and skin-structure infections, as well as community-acquired and hospital-acquired pneumonias. The company was founded in 2005 and is headquartered in Alameda, CA. | Health Technology |
